Personalised mRNA Cancer Vaccines & Immunotherapy: The New Oncology Frontier

 

Personalised mRNA Cancer Vaccines & Immunotherapy: The New Oncology Frontier

UPSC GS-III: Science & Technology (Biotechnology, Health & Public Policy)

Syllabus & Core Themes

• GS Paper-III: Biotechnology and its applications in health; Developments and their applications and effects in everyday life; Issues relating to intellectual property rights (IPR) and healthcare affordability.

• GS Paper-II: Issues relating to development and management of Social Sector/Services relating to Health.

The Mechanism: How Personalised mRNA Vaccines Work

Unlike traditional vaccines that target foreign pathogens (viruses or bacteria), therapeutic cancer vaccines train the body to eliminate its own mutated cells.

Tumour Biopsy ──► Genome Sequencing ──► Identify "Neoantigens" (Unique Mutations)
                                                       │
                                                       ▼
                                            Synthetic mRNA Vaccine
                                            (Codes up to 34 Neoantigens)
                                                       │
                                                       ▼
         Inject into Patient ──► Cells Produce Neoantigens ──► T-Cells Primed to Kill Tumour

• Neoantigens: Proteins found exclusively on the surface of mutated cancer cells. They act as the molecular "fingerprint" of an individual's specific tumor.

• mRNA Technology: Delivers a genetic blueprint instructing host cells to synthesize these neoantigens temporarily. This primes cytotoxic T-lymphocytes with immunological memory to prevent recurrence or metastasis.

• Combination with Immune Checkpoint Inhibitors (ICIs):

  • The Problem: Cancer cells produce proteins (like PD-L1) that bind to T-cell receptors (PD-1), acting as a "brake" to shut down the immune response.

  • The Synergy: Drugs like Keytruda (Pembrolizumab) block this brake (PD-1 pathway), while the mRNA vaccine primes the T-cells to identify the target, achieving a synergistic anti-tumor attack.

Traditional Chemotherapy vs. mRNA Immunotherapy

Feature	Conventional Chemotherapy	Personalised mRNA Immunotherapy
Mechanism	Non-specific cytotoxic agents killing rapidly dividing cells.	Instructs the host immune system to selectively target tumour neoantigens.
Specificity	Low (damages healthy hair follicles, gut lining, bone marrow).	High (precision targeting restricted to tumor cells).
Immunological Memory	None (action ceases when drug leaves the bloodstream).	Yes (T-cell memory lowers long-term recurrence risk).
Side-Effect Profile	Severe systemic toxicity, immunosuppression.	Mostly localized/mild (fatigue, injection-site pain, chills).

Indian Healthcare Context: Opportunities & Bottlenecks

1. Epidemiological Disparity

• The current breakthrough is clinically validated for advanced melanoma (skin cancer), which accounts for only ~0.26% of cancer cases in India (GLOBOCAN).

• India’s major cancer burden involves oral cavity, breast, cervical, and lung cancers—requiring customized clinical trials before these platforms can address domestic health priorities.

2. Affordability & Out-of-Pocket Expenditure (OOPE)

• Immunotherapy remains prohibitively expensive. Studies from institutions like Tata Memorial Hospital indicate that fewer than 2% of eligible Indian patients can access drugs like Pembrolizumab due to high costs.

• Adding a bespoke, patient-specific mRNA formulation further escalates logistical and manufacturing costs.

3. Infrastructure Needs

• Requires high-throughput next-generation sequencing (NGS), rapid synthetic mRNA manufacturing pipelines, and strict cold-chain logistics across regional oncology centers.

UPSC Practice Question (Prelims)

Q. With reference to recent developments in biotechnology and medicine, consider the following statements regarding "Neoantigens" and "mRNA Cancer Vaccines":

1. Neoantigens are foreign proteins produced exclusively by pathogenic viruses infecting human cells.

2. Personalised mRNA cancer vaccines are designed using genetic sequencing of an individual patient's tumour sample.

3. Monoclonal antibodies targeting the PD-1/PD-L1 pathway act by removing the inhibitory signals that prevent T-cells from attacking cancer cells.

Which of the statements given above are correct?

• (a) 1 and 2 only

• (b) 2 and 3 only

• (c) 1 and 3 only

• (d) 1, 2 and 3

Correct Answer: (b)

Explanation: Statement 1 is incorrect because neoantigens are mutated proteins produced by cancerous human cells, not viral pathogens. Statements 2 and 3 are correct.